Genedx Holdings CORP 10-Q quarterly reports

GeneDx Holdings Corp. announced its Q2 2026 financial results, showing an 11% increase in total revenue to $114.4 million, but also a net loss of $17.7 million.

GeneDx Holdings Corp. reported significant revenue growth and reduced net losses for the third quarter and first nine months of 2025, driven by increased diagnostic test volumes and the acquisition of Fabric Genomics.

GeneDx Holdings Corp. reported a significant financial turnaround in the second quarter of 2025, moving from a net loss to a net income and generating positive operating cash flow, fueled by a substantial increase in diagnostic test revenue and the integration of Fabric Genomics.

GeneDx Holdings Corp. announces a 40% increase in total revenue for the first quarter of 2025, primarily driven by growth in exome and genome sequencing revenues.

GeneDx Holdings Corp. saw a significant increase in revenue during the third quarter of 2024, primarily driven by higher diagnostic test volumes and improved reimbursement rates.

GeneDx Holdings Corp. saw a significant increase in revenue during the second quarter of 2024, primarily driven by higher demand for its whole exome and genome sequencing services.

GeneDx Holdings Corp. saw a significant increase in revenue during the first quarter of 2024, primarily due to higher demand for its whole exome and genome sequencing services.